Tharimmune (THAR) News Today → Biden replacement revealed? (From Paradigm Press) (Ad) Free THAR Stock Alerts $0.36 0.00 (0.00%) (As of 04/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Tharimmune, Inc. (NASDAQ:THAR) Expands By 37.3%americanbankingnews.com - April 29 at 5:40 AMTharimmune, Inc. (THAR)finance.yahoo.com - April 24 at 12:58 PMTharimmune Inc THARmorningstar.com - April 18 at 12:44 AMTharimmune forms advisory board to guide drug developmentinvesting.com - April 16 at 11:06 PMTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialmsn.com - February 21 at 10:30 AMTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Diseasemsn.com - February 20 at 7:01 PMTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidatefinanznachrichten.de - February 20 at 8:27 AMTharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidatefinance.yahoo.com - February 20 at 8:27 AMTharimmune’s Active Common Stock Shares Updatemsn.com - February 9 at 10:29 AMTharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitisfinance.yahoo.com - February 5 at 9:23 AMTharimmune, Inc.: Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Updatefinanznachrichten.de - January 29 at 12:32 PMTharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patientsfinance.yahoo.com - December 11 at 8:16 AMTharimmune, Inc. Announces Closing of $11 Million Public Offeringfinance.yahoo.com - November 30 at 8:13 PMWhy Tharimmune Stock (THAR) Is Down 70% Todaymsn.com - November 30 at 3:12 PMWhy Is Liver Disease Focused Tharimmune Stock Trading Higher Today?msn.com - November 29 at 1:49 AMTharimmune Shares Hit 52-Week Low After Public Offering Pricesmarketwatch.com - November 29 at 1:49 AMTharimmune announces pricing of $10 million public offeringmsn.com - November 29 at 1:49 AMCrude Oil Surges 2%; Tharimmune Shares Plummetmarkets.businessinsider.com - November 29 at 1:49 AMTharimmune, Inc. Announces Pricing of $10 Million Public Offeringfinance.yahoo.com - November 29 at 1:49 AMWhy Is Tharimmune (THAR) Stock Down 70% Today?investorplace.com - November 28 at 9:15 AMmarketbeat.com - November 21 at 6:06 AMWhy Is Tharimmune (THAR) Stock Up 113% Today?investorplace.com - November 7 at 9:07 AM Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 THAR Media Mentions By Week THAR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THAR News Sentiment▼0.020.33▲Average Medical News Sentiment THAR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THAR Articles This Week▼30▲THAR Articles Average Week Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Petros Pharmaceuticals News Today Cingulate News Today Artelo Biosciences News Today Longeveron News Today Exicure News Today Lipella Pharmaceuticals News Today NexImmune News Today Genprex News Today Avenue Therapeutics News Today Seelos Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THAR) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPub#1 election stockPorter & CompanyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBiden out June 13; Kamala won’t replace him?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersRevolutionizing Healthcare: A Biotech Stock You Can't IgnoreBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
